|
Aptalis Pharma knows its ABCs when it comes to treating CF and GI ailments. The company, formerly named Axcan Intermediate Holdings, develops and sells drugs mainly to treat cystic fibrosis (CF) and gastrointestinal (GI) conditions. Its Urso line treats liver disease; Carafate and Sulcrate treat ulcers; and Canasa and Salofalk offer relief for inflammatory bowel diseases. In addition, Aptalis Pharma markets Zenpep, a digestive aids for patients with exocrine pancreatic insufficiency, a condition associated with cystic fibrosis. The firm's products are primarily sold in North America and the European Union. Aptalis Pharma is a subsidiary of Axcan Holdings, which is controlled by TPG Capital.
|
| | | Contact Information | |
Address: |
22 Inverness Center Pkwy., Ste. 310
Birmingham, AL 35242
| | Phone: | 205-991-8085 | | Fax: | |
|
| Financial
Highlights | | Fiscal Year End: | September |
|
|
Key People
| | • |
President and CEO:
Frank A. G. M. Verwiel
| | • |
Senior Director Investor Relations and Communications:
Isabelle Adjahi
|
|
|
Industry Information
| |
Sector: | |
Industry: |
|
|
